129 MUTATION IN TET2 OR TP53 PREDICTS POOR SURVIVAL IN PATIENTS WITH MYELODYSPLASTIC SYNDROME RECEIVING HYPOMETHYLATING TREATMENT OR STEM CELL TRANSPLANTATION. (April 2015)